Systemic Immune–Inflammation Index Predicts New-Onset Atrial Fibrillation After St Elevation Myocardial Infarction

Abstract

Aim: To investigate the predictive capacity of a systemic immune–inflammation index (SII) in detecting new-onset atrial fibrillation (NOAF) following ST segment elevation myocardial infarction (STEMI). Patients & methods: A total of 402 STEMI patients were enrolled in the study. The patients were divided into two groups according to NOAF development. Results: A cut-off point of 1,228,000 for SII was identified with 60% sensitivity and 78.1% specificity to predict NOAF following STEMI. According to pairwise analysis of receiver operating characteristic curve analysis, the predictive power of SII in detecting NOAF following STEMI was similar to high-sensitive C-reactive protein, and better than neutrophil-to-lymphocyte ratio or platelet-to-lymphocyte ratio. Conclusion: SII can be used as one of the independent predictors of NOAF following STEMI.

Keywords:

• atrial fibrillation
• ST segment elevation myocardial infarction
• systemic immune–inflammation index

Author contributions

All authors have substantial contributions to conception and design, or acquisition of data, analysis and interpretation of data; drafting the article or revising it critically for important intellectual content; final approval of the version to be published.

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.